Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects

Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects

ObjectiveTo confirm the efficacy and safety of incobotulinumtoxinA (Xeomin®, Merz Pharmaceuticals GmbH; total dose 400 U) in Japanese subjects with lower limb (LL) poststroke spasticity using the Modified Ashworth Scale spasticity score for the plantar flexors (MAS-PF).MethodsThis phase III study (J...

Full description

Bibliographic Details
Main Authors:	Yoshihisa Masakado, Hitoshi Kagaya, Kunitsugu Kondo, Yohei Otaka, Andrzej Dekundy, Angelika Hanschmann, Thorin L. Geister, Ryuji Kaji
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-03-01
Series:	Frontiers in Neurology
Subjects:	botulinum neurotoxin type A incobotulinumtoxinA treatment spasticity lower limb Japan
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2022.832937/full

Similar Items

Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA
by: Klemens Fheodoroff, et al.
Published: (2020-03-01)

Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis
by: Steffen Berweck, et al.
Published: (2022-08-01)

Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis
by: Jörg Wissel, et al.
Published: (2021-12-01)

Improvement in Quality-of-Life-Related Outcomes Following Treatment with IncobotulinumtoxinA in Adults with Limb Spasticity: A Pooled Analysis
by: Franco Molteni, et al.
Published: (2023-12-01)

Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults
by: Wolfgang H. Jost, et al.
Published: (2023-05-01)

Botulinum toxin A (IncobotulinumtoxinA) and pneumoperitoneum image-guided for hernia repair with loss of dominance
by: Sergio E. López-Juárez, et al.
Published: (2023-01-01)

Post hoc analysis of the improvement in shoulder spasticity and safety observed following treatment with incobotulinumtoxinA
by: Jörg Wissel, et al.

Outcomes of IncobotulinumtoxinA Injection on Myalgia and Arthralgia in Patients Undergoing Temporomandibular Joint Arthroscopy: A Randomized Controlled Trial
by: David Faustino Ângelo, et al.
Published: (2023-06-01)

Pain Reduction in Cervical Dystonia Following Treatment with IncobotulinumtoxinA: A Pooled Analysis
by: Alberto Albanese, et al.
Published: (2023-05-01)

Effects of Ultrasound-Guided Administration of Botulinum Toxin (IncobotulinumtoxinA) in Patients with Lateral Epicondylitis
by: Antonio Galván Ruiz, et al.
Published: (2019-01-01)

Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions
by: Koji Makino, et al.
Published: (2020-03-01)

Tolerability and Efficacy of Customized IncobotulinumtoxinA Injections for Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Study
by: Mandar Jog, et al.
Published: (2020-12-01)

Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study
by: Cynthia Comella, et al.
Published: (2022-01-01)

Russian consensus on the use of incobotulinumtoxinA in children with cerebral palsy for the treatment of spasticity and sialorrhea
by: A. L. Kurenkov, et al.
Published: (2022-04-01)

Spotlight on botulinum toxin and its potential in the treatment of stroke-related spasticity
by: Kaku M, et al.
Published: (2016-03-01)

Botulinum neurotoxin type A in the interdisciplinary treatment of sialorrhea in adults and children—update and practice recommendations
by: Wolfgang H. Jost, et al.
Published: (2023-12-01)

Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins
by: Harald Hefter, et al.
Published: (2021-02-01)

Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center
by: Adina Turcu-Stiolica, et al.
Published: (2021-07-01)

One21: A Novel, Customizable Injection Protocol for Treatment of the Forehead with IncobotulinumtoxinA
by: de Sanctis Pecora C
Published: (2020-02-01)

“Appropriate Treatment” and Therapeutic Window in Spasticity Treatment with IncobotulinumtoxinA: From 100 to 1000 Units
by: Giancarlo Ianieri, et al.
Published: (2018-03-01)

Factors Influencing the Surgical Decision in Dystonia Patients Referred for Deep Brain Stimulation
by: Carolina Gorodetsky, et al.
Published: (2021-07-01)

Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?
by: Fraint A, et al.
Published: (2016-02-01)

Tailored botulinum toxin type A injections in aesthetic medicine: consensus panel recommendations for treating the forehead based on individual facial anatomy and muscle tone
by: Anido J, et al.
Published: (2017-10-01)

IncobotulinumtoxinA in the treatment of sialorrhea in patients with infantile cerebral palsy
by: A. L. Kurenkov, et al.
Published: (2021-08-01)

Cost-Utility Analysis of Incobotulinumtoxin-A Compared With Conventional Therapy in the Management of Post-Stroke Spasticity in Romania
by: Adina Turcu-Stiolica, et al.
Published: (2020-01-01)

IncobotulinumtoxinA for the Treatment of Glabella and Forehead Dynamic Lines: A Real-Life Longitudinal Case Series
by: da Cunha ALG, et al.
Published: (2023-03-01)

Treatment of spasticity in patients with the consequences of traumatic brain injury
by: A. P. Kovalenko, et al.
Published: (2022-02-01)

Functional influence of botulinum neurotoxin type A treatment (Xeomin®) of multifocal upper and lower limb spasticity on chronic hemiparetic gait
by: Maurizio Falso, et al.
Published: (2012-05-01)

Characterization of SNARE Cleavage Products Generated by Formulated Botulinum Neurotoxin Type-A Drug Products
by: Jack Xie, et al.
Published: (2010-08-01)

Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience
by: Javier Martínez-Poles, et al.
Published: (2018-05-01)

Botulinum toxin therapy (Incobotulinumtoxin А) in the complex rehabilitation of adolescents with cerebral palsy (clinical case)
by: E. V. Kostenko, et al.
Published: (2018-05-01)

Spasticity syndrome in cerebral pathology: evaluation and clinical models
by: A. P. Kovalenko, et al.
Published: (2021-10-01)

Botulinum Toxin: From Poison to Possible Treatment for Spasticity in Spinal Cord Injury
by: Ramiro Palazón-García, et al.
Published: (2021-05-01)

Safety and Effectiveness of Repeated Botulinum Toxin A Intracavernosal Injections in Men with Erectile Dysfunction Unresponsive to Approved Pharmacological Treatments: Real-World Observational Data
by: François Giuliano, et al.
Published: (2023-06-01)

Ergonomic Recommendations in Ultrasound-Guided Botulinum Neurotoxin Chemodenervation for Spasticity: An International Expert Group Opinion
by: Philippe Lagnau, et al.
Published: (2021-03-01)

A Bayesian Network Meta-Analysis and Systematic Review of Guidance Techniques in Botulinum Toxin Injections and Their Hierarchy in the Treatment of Limb Spasticity
by: Evridiki Asimakidou, et al.
Published: (2023-03-01)

The Short-Term Impact of Botulinum Neurotoxin-A on Muscle Morphology and Gait in Children with Spastic Cerebral Palsy
by: Nicky Peeters, et al.
Published: (2022-09-01)

AbobotulinumtoxinA (Dysport<sup>®</sup>), OnabotulinumtoxinA (Botox<sup>®</sup>), and IncobotulinumtoxinA (Xeomin<sup>®</sup>) Neurotoxin Content and Potential Implications for Duration of Response in Patients
by: Malgorzata Field, et al.
Published: (2018-12-01)

A practical guide to botulinum neurotoxin treatment of shoulder spasticity 2: Injection techniques, outcome measurement scales, and case studies
by: Jörg Wissel, et al.
Published: (2022-12-01)

Comments on Immunogenicity Associated with Botulinum Toxin Treatment. <i>Toxins</i> 2019, <i>11</i>, 491
by: Keith Foster, et al.
Published: (2020-01-01)